Trifecta Clinical, a global clinical technology solutions provider, has partnered with SAFE-BioPharma to implement the SAFE-BioPharma digital identity and signature standard across its application platforms. The digital identity and signature standard provides standardized, high-assurance identity trust for cyber-transactions across the biopharmaceutical and healthcare sectors. This will accelerate the adoption of standards-based identity management, enhancing security, quality and compliance. The company also joined SAFE-BioPharma Association’s Vendor Partner Program.

“SAFE-BioPharma digital identity credentials will enhance Trifecta’s ability to quickly and securely exchange data with sponsors, CROs and consortiums, saving money and time. It will simplify complicated processes for our clients as well as investigators,” said Alden Meier, president of Trifecta Clinical.

The SAFE-BioPharma standard was established by the pharmaceutical industry with the participation of the EMA and the FDA to create and maintain an interoperable digital identity and signature standard that allows secure, trusted exchanges and legally-binding digital signatures. A distinguishing characteristic of the standard requires each digital identity to be closely bound to its user’s proven identity. This provides a high level of trust in the identity of its user and is the basis of its interoperability. SAFE-BioPharma identity credentials will be trusted by U.S. government agencies such as the NIH, FDA and other systems that are directly or indirectly cross-certified with SAFE-BioPharma.